gsk201304126k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending April 2013
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the interests of Directors or Persons Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising from the purchase of Ordinary Shares at a price of 1560.192 pence per Ordinary Share on 11 April 2013 as a result of the reinvestment of dividends paid on Ordinary Shares held in the GlaxoSmithKline ShareReward Plan (the Plan).
|
Sir Andrew Witty
|
Acquisition of 31 Ordinary Shares
|
|
Mr S Dingemans
|
Acquisition of 6 Ordinary Shares
|
|
Mr S M Bicknell
|
Acquisition of 46 Ordinary Shares
|
|
Mr R G Connor
|
Acquisition of 39 Ordinary Shares
|
|
Mr S A Hussain
|
Acquisition of 8 Ordinary Shares
|
|
Mr D S Redfern
|
Acquisition of 46 Ordinary Shares
|
|
Ms C Thomas
|
Acquisition of 46 Ordinary Shares
|
|
Mr P C Thomson
|
Acquisition of 20 Ordinary Shares
|
|
Dr P J T Vallance
|
Acquisition of 24 Ordinary Shares
|
|
Ms E Walmsley
|
Acquisition of 2 Ordinary Shares
|
|
Mrs V A Whyte
|
Acquisition of 30 Ordinary Shares
|
The Company and the above-mentioned persons were advised of this information on 12 April 2013.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
12 April 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: April 12, 2013
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc